Zoetis Stock Price, News & Analysis (NYSE:ZTS)

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Zoetis announced a quarterly dividend on Thursday, October 3rd. Shareholders of record on Tuesday, October 22nd will be given a dividend of $0.164 per share on Monday, December 2nd. This represents a $0.66 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend is Monday, October 21st. View Zoetis' Dividend History.

Zoetis announced that its Board of Directors has initiated a share repurchase plan on Wednesday, December 12th 2018, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 4.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its shares are undervalued.

Zoetis Inc (NYSE:ZTS) issued its earnings results on Tuesday, August, 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analysts' expectations of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The firm's revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.77 EPS. View Zoetis' Earnings History.

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Zoetis.

Zoetis will be holding an earnings conference call on Thursday, November 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Zoetis issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $3.53-3.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.49. The company issued revenue guidance of $6.18-6.28 billion, compared to the consensus revenue estimate of $6.19 billion.

15 analysts have issued 1 year target prices for Zoetis' shares. Their forecasts range from $86.00 to $145.00. On average, they anticipate Zoetis' stock price to reach $124.40 in the next twelve months. This suggests that the stock has a possible downside of 1.6%. View Analyst Price Targets for Zoetis.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Press coverage about ZTS stock has trended very negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Zoetis earned a media sentiment score of -3.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the near term. View News Stories for Zoetis.

Zoetis saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,420,000 shares, an increase of 30.8% from the August 30th total of 3,380,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 2.3 days. Currently, 0.9% of the shares of the stock are sold short. View Zoetis' Current Options Chain.

Some companies that are related to Zoetis include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Transocean (RIG), Gran Tierra Energy (GTE) and Micron Technology (MU).

Zoetis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include CIBC Private Wealth Group LLC (0.49%), Envestnet Asset Management Inc. (0.23%), Artemis Investment Management LLP (0.17%), Robeco Institutional Asset Management B.V. (0.12%), Strs Ohio (0.11%) and Hexavest Inc. (0.08%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

ZTS stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Strs Ohio, Varma Mutual Pension Insurance Co, DAVENPORT & Co LLC, Nippon Life Global Investors Americas Inc., Decatur Capital Management Inc., Gateway Investment Advisers LLC and Heritage Investors Management Corp. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

ZTS stock was acquired by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Robeco Institutional Asset Management B.V., Copper Rock Capital Partners LLC, State of Alaska Department of Revenue, Oakbrook Investments LLC, Commerzbank Aktiengesellschaft FI, Envestnet Asset Management Inc. and Park National Corp OH. View Insider Buying and Selling for Zoetis.

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZTS stock can currently be purchased for approximately $126.45.

Zoetis has a market capitalization of $60.39 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

The official website for Zoetis is http://www.zoetis.com/.

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]